InFocus Volume 6 Issue 4




Funding Opportunities

In the News

Upcoming Events



CCN Investigators Present New Findings at AAIC 2014

Researchers from the Center for Cognitive Neurology (CCN), NYU School of Medicine, and the Nathan S. Kline Research Institute presented new findings at the 2014 Alzheimer's Association International Conference (AAIC) in Copenhagen, Denmark, July 12 – 17, 2014.

The Alzheimer's Association International Conference (AAIC), the world's largest forum of its kind, annually brings together researchers from around the world to report and discuss groundbreaking research and information on the cause, diagnosis, treatment and prevention of Alzheimer's disease and related disorders. Novel treatment approaches, new diagnostic and treatment-monitoring technologies, and recent findings on potentially modifiable risk factors for the disease were among the topics covered.

Focusing on discovery, progress, and change, as part of the Alzheimer's Association's research program, AAIC serves as a catalyst for generating new knowledge about dementia and fostering a vital, collegial research community. Thousands attended and more than 2,000 abstracts were presented -- all in an effort to advance the discovery of scientific breakthroughs leading to methods of prevention, treatment, and ultimately, a cure for Alzheimer's disease.

The Center for Cognitive Neurology had a strong presence at the event.

The following highlights key presentations and posters of CCN members and NYU faculty.  For more information, please visit the CCN AAIC Media Tip Sheet or the AAIC website


Tau Immunotherapies”
 Sigurdsson, E.M., PhD

“Mitochondria And Death Receptors: Key Targets For Amyloid Toxicity In The Cerebral Vasculature “ 
Silvia Fossati, PhD, Patrizia Giannoni, Mar Hernandez, Joan Montaner, Jorge Ghiso, Agueda Rostagno

“Targeting the Shared Pathological Conformers of both Aß and Hyperphosphylated Tau with a Conformationally Selective Monoclonal Antibody”
Thomas Wisniewski , Eleanor Drummond, Krystal Herline, Yanjie Sun, Fernando Goni

“Tau Antibody Derivatives as Diagnostic Imaging Agents for Tauopathies”
 Krishnaswamy, S., Lin, Y., Rajamohamedsait, W.J., Rajamohamedsait, H.B., Krishnamurthy, P.K., Pedersen, J.T., Stavenhagen, J.B., Sigurdsson, E.M.,

“One Year Global Outcome of a Comprehensive, Individualized, Person Centered Management (CI ‐ PCM) Program + Memantine in Advanced AD: A Randomized Controlled Trial”
Reisberg, B., Boksay, I., Golomb, J., Agarwal, S., Ghimire, S., Shaker, H., Torossian, C., Xu, J., Kenowsky, S.

Poster Presentations:

“Tau Antibody Derivatives as Diagnostic Imaging Agents for Tauopathies” 
Krishnaswamy, S., Lin, Y., Rajamohamedsait, W.J., Rajamohamedsait, H.B., Krishnamurthy, P.K., Pedersen, J.T., Stavenhagen, J.B., Sigurdsson, E.M.

“Hippocampal Size Predicts Delayed Primacy Performance In Cognitively Intact Elderly Participants”
Davide Bruno, Michel Grothe, Jay Nierenberg, Stefan Teipel, and Nunzio Pomara

“Proteomic Analysis Of Archived Alzheimer’s Disease Brain Tissue Using Laser Capture Micro dissection And LC-MS”  
Eleanor Drummond, Beatrix Ueberheide, Thomas Wisniewski

“Increased CSF Matrix Metalloproteinase-9(MMP-9) And Reduced White Matter Integrity In Healthy Elderly”
Nunzio Pomara, Chelsea Reichert,  Jay Nierenberg, Matthew R. Halliday, Abhay P. Sagare, Blas Frangione, Berislav V. Zlokovic

“Uptake of Tau Antibodies into PHF Pre-Treated Transfected Human Neuroblastoma Cells Leads To A Decrease In Tau Protein Levels.” 
D.B. Shamir, Nina Rosenqvist, Suhail Rasool, Jan T. Pedersen, Einar M. Sigurdsson

“Testing of Innate Immunity Stimulation via TLR9 on Cerebral Amyloid Angiopathy use in Non-Human Primates.”
Henrieta Scholtzova , Pramod N Nehete, Bharti P Nehete, Andrea Holmes, Meredith Spadaccia, Lisa M Sprinzen, Mohsin Jamal, Rachel L Sabado, Lawrence E Williams, Thomas Wisniewski

“Tau Antibody-Mediated Prevention Of Seeding Of Tau Pathology And Associated Toxicity”
Erin E. Congdon, Suhail Rasool, Jiaping Gu, Einar M. Sigurdsson

“Anti-Conformational Monoclonal Antibody with Selective Preference for PrPRes Strains from Different Animal Species and Humans”
Fernando Goni , Frances Prelli, Eleanor Drummond, Krystal Herline, Mithchell Marta3, Yanjie Sun, Bernardino Francesco Ghetti, Thomas Wisniewski 

“Monitoring Tau Pathology And Monoclonal Antibodies In Vivo By Two-Photon Imaging”
Lin,Y., Gu,J., Rajamohamedsait,H.B., Rajamohamedsait,W.J., Sigurdsson, E.M.

“Sleep Disordered Breathing in the Elderly and Risk for Alzheimer’s disease using FDG-PET”
Tyler Gumb, Janna Mantua, Yi Li, Ricardo Osorio

“Mucosal Immunization to Prevent Chronic Wasting Disease (CWD) in Deer”
Fernando Goni , Candace Mathiason, Krystal Herline, Jeanette Hayes-Klug, Amy Nalls, Kelly Anderson, Veronica Estevez, Lucia Yim, David Brown, Jose Alejandro Chabalgoity, Edward Hoover, Thomas Wisniewski 

Sadowski Laboratory Identifies New Compound Shown to Reduce Levels of Amyloid in Alzheimer Brains

Martin J. Sadowski, MD, PhD, associate professor of neurology, psychiatry, and biochemistry and molecular pharmacology, and colleagues have identified a compound, 2-PMAP, which, in animal studies reduced by more than 50 percent levels of amyloid protein in the brain associated with Alzheimer's disease. The research was published on June 3 in Annals of Neurology.

The 2-PMAP molecule is non-toxic in mice, is easily penetrable into the brain, and lowers the production of amyloid beta and associated amyloid deposits. The prime target for Alzheimer's prevention is amyloid beta. Dr. Sadowski and colleagues screened a library of compounds and found that 2-PMAP reduced the production of amyloid beta's mother protein, known as amyloid precursor protein (APP). The APP protein normally is cut by enzymes in a way that leaves amyloid beta as one of the fragments. Dr. Sadowski's team found that 2-PMAP, even at low, non-toxic concentrations, significantly reduced APP production in test cells, lowering amyloid beta levels by 50 percent or more. The scientists subsequently found that 2-PMAP had essentially the same impact on APP and amyloid beta in the brains of living mice. The mice were engineered to have the same genetic mutations found in Alzheimer's patients with a hereditary form of the disease, causing overproduction of APP and Alzheimer's-like amyloid deposits. A five-day treatment with 2-PMAP lowered brain levels of APP and, even more so, levels of amyloid beta. Four months of treatment sharply reduced the amyloid deposits and prevented the cognitive deficits that are normally seen in these transgenic mice as they get older.

The researchers are now working to make chemical modifications to the compound to improve its effectiveness. But 2-PMAP already seems to have advantages over other amyloid-lowering compounds. One is that it can cross efficiently from the bloodstream to the brain, and thus doesn't require complex modifications that might compromise its effects on APP. The compound also appears to have a highly selective effect on APP production, by interfering with the translation of APP's gene transcript into the APP protein itself. The researchers hope that someday a treatment based on the molecule could be used to ward off the neurodegenerative disease since it may be safe enough to be taken daily over many years.

U.S. Patent No. 8,658,677 was recently issued for the 2-PMAP compound. Funding for the research was provided in part by the National Institutes of Health.

Read more about the Sadowski Lab's 2-PMAP findings.

NYU Langone Medical Center Launches Clinical Research Data Management Resource

A new Core resource to support the collection, processing and management of clinical research study data is being launched by NYU Langone Medical Center (NYULMC). DataCore, based in the Medical Center IT Department and overseen by the Clinical and Translational Science Institute and its Population Health, Biomedical Informatics and Translational Library Programs will provide a range of services. Key amongst these services is the development of data management, data integrity monitoring and electronic data capture components of grants and protocols. Experience thus far has indicated that the participation of the Core in grant and protocol development will strengthen the study and increase the probability of peer-review, competitive funding. DataCore will also include capabilities that leverage the NYULMC Enterprise Data Warehouse and the use of large clinical data linked to 'omics' datasets in research. The clinical research data management goals of DataCore are to:

  • improve the quality of clinical research projects;
  • ensure the highest level of data integrity;
  • assist in meeting regulatory requirements for clinical research; and
  • enable NYULMC to become more competitive for grant and contract funding.

DataCore will make extensive use of currently available and new electronic data capture (EDC) systems and can develop clinical research study systems and registries to streamline data collection and facilitate data integrity monitoring. DataCore will also offer consultations to researchers on study development, the selection and development of EDC systems, research forms design and the use of related technologies. DataCore will also provide educational seminars, develop a forms library and assist in the development of data standards.

If requested, the DataCore team will help researchers with budget development. They will use several uniquely tailored EDC and data management options to accommodate the amount of funding clinical researchers have for specific projects. The services that DataCore plans to provide range from a do-it-yourself system that would be free of charge using NIH CTSA funded software- REDCap , to a comprehensive service which includes data management, data integrity monitoring, electronic data capture systems development and regulatory reporting.

It is envisioned that DataCore will become a long-term resource for clinical research investigators and will position NYULMC as a clinical research center with strong data management and systems development expertise. DataCore will result in an expansion of our current Data Coordinating Center that provides support for large, long-term multicenter projects.

For more information, please contact Alex Bragat or James Robinson. In order to obtain the full benefit of the Unit's expertise, it is recommended to involve DataCore as the study is being developed, rather than once it is underway.

Written by: Sloka S. Iyengar, PhD., postdoctoral fellow at the Nathan Kline Institute, New York in the lab of Dr. Helen Scharfman, James Robinson, Acting Director, DataCore at NYU Langone Medical Center, and John Speakman, Senior Director for Research IT at NYU Langone Medical Center.

In the Spotlight...

Mohammed Osman Sheikh, MD
Clinical Trials Coordinator
Center for Cognitive Neurology
NYU Langone Medical Center

Mohammed Sheikh joined NYU Langone earlier this year and serves as a clinical trials coordinator at the Center for Cognitive Neurology. He assists with the coordination and recruitment of study subjects, is directly involved in the preparation of all IRB-related materials for new studies, engages with study investigators on enrollment ideas and completes chart reviews to determine subject eligibility. He obtained his Bachelor of Science degree from St. John's University (Jamaica, NY), with a major in Biology and double minor in Chemistry and Philosophy of Science; and earned his MD from Ross University School of Medicine (Dominica, West Indies).

What is your area of focus?
Primarily, I work with various clinical studies that focus on pharmacological and non pharmacological interventions, such as transmagnetic stimulation, to both prevent and slow down the progression of memory loss in the elderly population. There have been a number of breakthroughs in disease prevention and we are working with monoclonal antibodies, B-secretase inhibitors and intranasal insulin to name a few of our approaches to combat the disease.

What is the greatest challenge you face in your work?
In my short time working with the elderly population with memory loss I have had the privilege of meeting many people with a wide range of severity of the disease. One of the challenges in this field is sitting down with a participant and telling him/her that he/she does not meet the criteria for a particular study that he/she wanted to be a part of and was so excited to enroll in. On the bright side, we can always try to find another study that hopefully the individual is a good match for.

You have personal experience in the field of psychiatry, with knowing people who have been diagnosed with Schizophrenia. Tell us about this experience and what you believe to be your calling in life?
I took a trip to Pakistan during my third year of medical school and reconnected with an old friend I hadn't seen in years. She wasn't the same person I had met a few years prior. She was diagnosed with Schizophrenia, and I was told to stay away. She was labeled as "crazy," and shunned by the rest of her family. Inquiring into her illness and medications was a taboo. I began to think to myself, if she had proper treatment, would she have been ostracized? Is there anything else that could have been done? This inspired me to join the profession of psychiatry and help empower individuals with mental health. I want to break the taboo of treating mental illness like something that needs to be kept a secret.

You envision going back to Pakistan at some point and working with Doctors without Borders. What exactly is this program? What benefit does it provide?
Doctors without Borders was created in 1971 by a small group of French doctors with the core belief that all individuals have the right to medicine regardless of religion, race, creed or political affiliation. It is a non-governmental organization with a focus on medical-based projects in developing countries and war-torn areas. It involves a mission team comprised of various specialist physicians, nurses and medical staff who help provide services like vaccinations, medications, surgical treatments, nutrition, clean water and lastly and most importantly, psychological support.

Would you share with us your professional/personal aspirations? Where do you see yourself in 10 years?
Psychiatry is the field I belong to and fell in love with before knowing what it was. The diversity that psychiatry has to offer, its intellectual stimulation and holistic approach are a few of the reasons why I chose this field. I see myself in 10 years with a family, teaching, doing research, and raising awareness about mental illness.

What or who inspires you?
I would have to say my inspiration to become a physician came from my mother. As an obstetrician she taught me that by listening alone, she could change the treatment plans for a patient and in the long run, their well-being. It was through her ideas of individualized treatments that I learned how important it was to listen to the patient in order to understand their needs. She inspired me to combine both physical and mental health in my treatment plans.

How would a colleague describe you?
I hope my colleagues would describe me as a team player, one who they can relay upon, especially when things get messy. Also, as someone who is well organized and can plan for the future.

Funding Opportunities

Young Investigator Research Grant

The goal of the Frangione Foundation, established in 2009 by Blas Frangione, MD, PhD, Professor of Pathology and Psychiatry, is to support research on neuroscience relevant to neurodegenerative diseases.

$40,000 for one year with potential for renewal.

Deadline: October 1, 2014


Alzheimer's Disease Research Program

BrightFocus provides research funds for U.S. domestic as well as international researchers pursuing pioneering research leading to a greater understanding of Alzheimer's disease.

The maximum award value of the ADR Standard Award is US $250,000, payable over three years.

Interested post doctoral researchers should apply for the ADR Research Fellowship, a two year award with a maximum value of US $100,000.

Deadline: October 14, 2014 for 2015 Awards Cycle


Immune and Inflammatory Mechanisms in Alzheimer's Disease (R01)

The goal of this FOA is to establish the role of the brain innate immune system, the systemic immune system, and the crosstalk and changes with age between the two in the development and progression of Alzheimer's disease. An interdisciplinary and integrative research approach to identify the cell networks and meditators of the brain and systemic immune and inflammatory systems is expected to give greater insight into the etiological mechanisms underlying Alzheimer's disease.

Deadline: January 25th 2015


In the News

Inexpensive Alzheimer's tests offer promise
USA Today- July 13th, 2014
Dr. Ralph Nixon comments on new research to be presented this week at the Alzheimer's Association International Conference in Denmark, scientists show progress developing detection methods that rely on the blood, sense of smell and protein build-up in the eyes. All have been tested in dozens to hundreds of patients.

Alzheimer's blood test may predict who gets disease
CBS This Morning- July 9th, 2014
Dr. James Galvin
In a new study, researchers report 87 percent accuracy in predicting who will get Alzheimer's disease within a year. Dr. James Galvin, neurologist at NYU Langone Medical Center, joins the "CBS This Morning" co-hosts to talk about the race to develop a simple test for the incurable disease.

Upcoming Events

Save the Date- ADC 25 Year Anniversary

Monday, October 27th, 2014
Alumni Hall B and Smilow Multipurpose Room

This event brings together faculty, staff and trainees from several disciplines to raise awareness of the ongoing research activities as they relate to the field of cognitive neurology and brain aging. Opening remarks will be made by Dean Robert Grossman, MD. Presentations will feature keynote guest speaker, John Trojanowski, MD, Ph.D., Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, whose research currently focuses on molecular mechanisms of neuron dysfunction, degeneration and death in normal aging and in neurodegenerative diseases. Scientific lectures will be presented by NYU investigators, followed by a comprehensive poster session and reception. Additional features of the program will be announced in a follow-up notice.

Posters will be solicted in mid August through listserv email. For more information contact Camy Sleeman

Sunday, October 19th, Riverside Park

The Walk to End Alzheimer's is an annual event organized through the Alzheimer's Association that has raised over $300 million nationally since it began in 1989. As a friend of the Alzheimer's Association and to thank them for the support they give to patients, caregivers and researchers, the Silberstein Alzheimer's Institute will return as a sponsor for this year's event, and will host a booth.

Ways to join:
-Volunteers are needed to help represent the work being done by CCN member labs and clinics. Study coordinators are welcome to join the table to conduct recruitment.
-The CCN Team, "Aging with Excellence" is currently recruiting walkers.

To participate on the team or at the booth, contact Camy Sleeman at or join through the team webpage.


Annual Rodolfo Llinás Lecture

September 8th, 2014
4 pm, Alumni Hall B
NET-fMRI of Large-Scale Brain Networks: Mapping Dynamic Connectivity during Epochs of Synaptic and System Consolidation
Presented by: Nikos K. Logothetis, PhD
Max Planck Institute for Biological Cybernetics
Hosted by: NYU Neuroscience Institute

Reception to Follow

Annual ADC Educational Spanish in Spanish

October 1st, 2014
1 pm, Alumni Hall B
Alzheimer's Care in the Hispanic Community
Hosted by: NYU Alzheimer's Disease Center

Neuroscience Seminar Series at Nathan Kline Institute

September 18th, 2014
12-1 pm, Nathan Kline Institute, Conference Room B
"Using Mass Spectometry to Study Cell Signaling in Neurons"
Presented by Thomas Neubert 
Associate Professor of Biochemistry and Molecular Pharmacology
Director, Proteomics Core, NYU Langone
Hosted by: Ralph Nixon, MD, PhD


  • Mariga A, Zavadil J, Ginsberg SD, Chao MV. Withdrawal of BDNF from hippocampal cultures leads to changes in genes involved in Synaptic function. Dev Neurobiol. 2014 Jul 25. doi: 10.1002/dneu.22216. [Epub ahead of print] PubMed PMID:25059794.
  • Saba S, Blum S. Aphasia due to isolated infarction of the corpus callosum. BMJ Case Rep. 2014 Jun 12;2014. pii: bcr2014204316. doi: 10.1136/bcr-2014-204316. PubMed PMID: 24925538.
  • Zhang G, Deinhardt K, Neubert TA. Stable isotope labeling by amino acids in cultured primary neurons. Methods Mol Biol. 2014;1188:57-64. doi: 10.1007/978-1-4939-1142-4_5. PubMed PMID: 25059604.
  • Varga AW, Kang M, Ramesh PV, Klann E. Effects of acute sleep deprivation on motor and reversal learning in mice. Neurobiol Learn Mem. 2014 Jul 18. pii: S1074-7427(14)00128-2. doi: 10.1016/j.nlm.2014.07.001. [Epub ahead of print] PubMed PMID: 25046627.
  • Ma T, Klann E. PERK: a novel therapeutic target for neurodegenerative diseases? Alzheimers Res Ther. 2014 May 29;6(3):30. doi: 10.1186/alzrt260. eCollection 2014. PubMed PMID: 25031640; PubMed Central PMCID: PMC4075240.
  • Zweig YR, Galvin JE. Lewy body dementia: the impact on patients and caregivers. Alzheimers Res Ther. 2014 Apr 25;6(2):21. doi: 10.1186/alzrt251. eCollection 2014. Review. PubMed PMID: 25031635; PubMed Central PMCID: PMC4054937.
  • Orczyk C, Taneja SS, Rusinek H, Rosenkrantz AB. Assessment of change in prostate volume and shape following surgical resection through co-registration of in-vivo MRI and fresh specimen ex-vivo MRI. Clin Radiol. 2014 Jul 22. pii: S0009-9260(14)00322-5. doi: 10.1016/j.crad.2014.06.012. [Epub ahead of print] PubMed PMID: 25062923.
  • Albers MW, Gilmore GC, Kaye J, Murphy C, Wingfield A, Bennett DA, Boxer AL, Buchman AS, Cruickshanks KJ, Devanand DP, Duffy CJ, Gall CM, Gates GA, Granholm AC, Hensch T, Holtzer R, Hyman BT, Lin FR, McKee AC, Morris JC, Petersen RC, Silbert LC, Struble RG, Trojanowski JQ, Verghese J, Wilson DA, Xu S, Zhang LI. At the interface of sensory and motor dysfunctions and Alzheimer's disease. Alzheimers Dement. 2014 Jul 8. pii: S1552-5260(14)00642-6. doi: 10.1016/j.jalz.2014.04.514. [Epub ahead of print] Review. PubMed PMID: 25022540.
  • Rao MV, McBrayer MK, Campbell J, Kumar A, Hashim A, Sershen H, Stavrides PH, Ohno M, Hutton M, Nixon RA. Specific Calpain Inhibition by Calpastatin Prevents Tauopathy and Neurodegeneration and Restores Normal Lifespan in Tau P301L Mice. J Neurosci. 2014 Jul 9;34(28):9222-34. doi: 10.1523/JNEUROSCI.1132-14.2014. PubMed PMID: 25009256.
  • Takano N, Sarfraz Y, Gilkes DM, Chaturvedi P, Xiang L, Suematsu M, Zagzag D, Semenza GL. Decreased Expression of Cystathionine β-Synthase Promotes Glioma Tumorigenesis. Mol Cancer Res. 2014 Jul 3. pii: molcanres.0184.2014. [Epub ahead of print] PubMed PMID: 24994751.
  • Huynh TN, Santini E, Klann E. Requirement of Mammalian target of rapamycin complex 1 downstream effectors in cued fear memory reconsolidation and its persistence. J Neurosci. 2014 Jul 2;34(27):9034-9. doi: 10.1523/JNEUROSCI.0878-14.2014. PubMed PMID: 24990923; PubMed Central PMCID: PMC4078080.
  • Coureaud G, Thomas-Danguin T, Wilson DA, Ferreira G. Neonatal representation of odour objects: distinct memories of the whole and its parts. Proc Biol Sci. 2014 Aug 22;281(1789). pii: 20133319. doi: 10.1098/rspb.2013.3319. PubMed PMID: 24990670; PubMed Central PMCID: PMC4100496.
  • Kim S, Ziff EB. Calcineurin mediates synaptic scaling via synaptic trafficking of Ca2+-permeable AMPA receptors. PLoS Biol. 2014 Jul 1;12(7):e1001900. doi: 10.1371/journal.pbio.1001900. eCollection 2014 Jul. PubMed PMID: 24983627; PubMed Central PMCID: PMC4077568.
  • Coureaud G, Thomas-Danguin T, Datiche F, Wilson DA, Ferreira G. Differential memory persistence of odor mixture and components in newborn rabbits: competition between the whole and its parts. Front Behav Neurosci. 2014 Jun 16;8:211. doi: 10.3389/fnbeh.2014.00211. eCollection 2014. PubMed PMID: 24982622; PubMed Central PMCID: PMC4059275.
  • Sarro EC, Wilson DA, Sullivan RM. Maternal regulation of infant brain state. Curr Biol. 2014 Jul 21;24(14):1664-9. doi: 10.1016/j.cub.2014.06.017. Epub 2014 Jul 3. PubMed PMID: 24980504; PubMed Central PMCID: PMC4108557.
  • Pankiewicz JE, Guridi M, Kim J, Asuni AA, Sanchez S, Sullivan PM, Holtzman DM, Sadowski MJ. Blocking the apoE/Aß interaction ameliorates Aß-related pathology in APOE ¿2 and ¿4 targeted replacement Alzheimer model mice. Acta Neuropathol Commun. 2014 Jun 28;2(1):75. [Epub ahead of print] PubMed PMID: 24972680.
  • Mosconi L, Murray J, Davies M, Williams S, Pirraglia E, Spector N, Tsui WH, Li Y, Butler T, Osorio RS, Glodzik L, Vallabhajosula S, McHugh P, Marmar CR, de Leon MJ. Nutrient intake and brain biomarkers of Alzheimer's disease in at-risk cognitively normal individuals: a cross-sectional neuroimaging pilot study. BMJ Open. 2014 Jun 24;4(6):e004850. doi: 10.1136/bmjopen-2014-004850. PubMed PMID: 24961717; PubMed Central PMCID: PMC4078781.
  • Sabharwal P, Wisniewski T. Novel Immunological Approaches for the Treatment of Alzheimer’s disease, Chinese Journal of Contemporary Neurology and Neurosurgery, 14: 139-151, 2014.  
  • Moster S, Wilson JA, Galetta SL, Balcer LJ. The King-Devick (K-D) test of rapid eye movements: A bedside correlate of disability and quality of life in MS. J Neurol Sci. 2014 Aug 15;343(1-2):105-9. doi: 10.1016/j.jns.2014.05.047. Epub 2014 Jun 2. PubMed PMID: 24954088.
  • Hoedt E, Zhang G, Neubert TA. Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) for Quantitative Proteomics. Adv Exp Med Biol. 2014;806:93-106. doi: 10.1007/978-3-319-06068-2_5. PubMed PMID: 24952180.
  • Adisetiyo V, Jensen JH, Tabesh A, Deardorff RL, Fieremans E, Di Martino A, Gray KM, Castellanos FX, Helpern JA. Multimodal MR Imaging of Brain Iron in Attention Deficit Hyperactivity Disorder: A Noninvasive Biomarker That Responds to Psychostimulant Treatment? Radiology. 2014 Aug;272(2):524-32. doi: 10.1148/radiol.14140047. Epub 2014 Jun 17. PubMed PMID: 24937545.
  • Yusupov A, Galvin JE. Vocalization in dementia: a case report and review of the literature. Case Rep Neurol. 2014 Apr 30;6(1):126-33. doi: 10.1159/000362159. eCollection 2014 Jan. PubMed PMID: 24926262; PubMed Central PMCID: PMC4036439.
  • Aronhime S, Calcagno C, Jajamovich GH, Dyvorne HA, Robson P, Dieterich D, Fiel MI, Martel-Laferriere V, Chatterji M, Rusinek H, Taouli B. DCE-MRI of the liver: effect of linear and nonlinear conversions on hepatic perfusion quantification and reproducibility. J Magn Reson Imaging. 2014 Jul;40(1):90-8. doi: 10.1002/jmri.24341. Epub 2013 Nov 4. PubMed PMID: 24923476; PubMed Central PMCID: PMC4058642.
  • Yang G, Lai CS, Cichon J, Ma L, Li W, Gan WB. Sleep promotes branch-specific formation of dendritic spines after learning. Science. 2014 Jun 6;344(6188):1173-8. doi: 10.1126/science.1249098. PubMed PMID: 24904169.
  • Devi L, Ohno M. PERK mediates eIF2α phosphorylation responsible for BACE1 elevation, CREB dysfunction and neurodegeneration in a mouse model of Alzheimer's disease. Neurobiol Aging. 2014 Oct;35(10):2272-81. doi: 10.1016/j.neurobiolaging.2014.04.031. Epub 2014 May 2. PubMed PMID: 24889041.
  • Chippendale T, Boltz M. The Neighborhood Environment: Perceived Fall Risk, Resources, and Strategies for Fall Prevention. Gerontologist. 2014 May 16. pii: gnu019. [Epub ahead of print] PubMed PMID: 24836115.
  • Lu W, Khatri L, Ziff EB. Trafficking of α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Receptor (AMPA) Receptor Subunit GluA2 from the Endoplasmic Reticulum Is Stimulated by a Complex Containing Ca2+/Calmodulin-activated Kinase II (CaMKII) and PICK1 Protein and by Release of Ca2+ from Internal Stores. J Biol Chem. 2014 Jul 4;289(27):19218-19230. Epub 2014 May 15. PubMed PMID: 24831007; PubMed Central PMCID: PMC4081956.
  • Zhu CW, Sano M, Ferris SH, Whitehouse PJ, Patterson MB, Galasko D, Schneider LS, Aisen PS. Alzheimer's Disease Cooperative Study Prevention Instrument Project assessing resource use and volunteer and paid work in healthy elders: a longitudinal study. J Am Geriatr Soc. 2014 May;62(5):985-8. doi: 10.1111/jgs.12816. PubMed PMID: 24828933; PubMed Central PMCID: PMC4023903.
  • Nixon RA. Alzheimer neurodegeneration, autophagy, and Abeta secretion: the ins and outs (comment on DOI 10.1002/bies.201400002). Bioessays. 2014 Jun;36(6):547. doi: 10.1002/bies.201400064. PubMed PMID: 24819351.
  • Llinás RR, Ustinin MN. Frequency-pattern functional tomography of magnetoencephalography data allows new approach to the study of human brain organization. Front Neural Circuits. 2014 Apr 29;8:43. doi: 10.3389/fncir.2014.00043. eCollection 2014. PubMed PMID: 24808829; PubMed Central PMCID: PMC4010750.
  • Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chételat G, Dubois B, Dufouil C, Ellis KA, van der Flier WM, Glodzik L, van Harten AC, de Leon MJ, McHugh P, Mielke MM, Molinuevo JL, Mosconi L, Osorio RS, Perrotin A, Petersen RC, Rabin LA, Rami L, Reisberg B, Rentz DM, Sachdev PS, de la Sayette V, Saykin AJ, Scheltens P, Shulman MB, Slavin MJ, Sperling RA, Stewart R, Uspenskaya O, Vellas B, Visser PJ, Wagner M; Subjective Cognitive Decline Initiative (SCD-I) Working Group. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement. 2014 May 3. pii: S1552-5260(14)00002-8. doi: 10.1016/j.jalz.2014.01.001. [Epub ahead of print] PubMed PMID: 24798886.
  • Barnes DC, Wilson DA. Sleep and olfactory cortical plasticity. Front Behav Neurosci. 2014 Apr 22;8:134. doi: 10.3389/fnbeh.2014.00134. eCollection 2014. Review. PubMed PMID: 24795585; PubMed Central PMCID: PMC4001050.
  • Ohno M. Roles of eIF2α kinases in the pathogenesis of Alzheimer's disease. Front Mol Neurosci. 2014 Apr 16;7:22. doi: 10.3389/fnmol.2014.00022. eCollection 2014. Review. PubMed PMID: 24795560; PubMed Central PMCID: PMC3997008.
  • Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimers Dement. 2014 May 2. pii: S1552-5260(14)00066-1. doi: 10.1016/j.jalz.2014.02.004. [Epub ahead of print] Review. PubMed PMID: 24795085.
  • Schnurman ZS, Frohman TC, Beh SC, Conger D, Conger A, Saidha S, Galetta S, Calabresi PA, Green AJ, Balcer LJ, Frohman EM. Retinal architecture and mfERG: Optic nerve head component response characteristics in MS. Neurology. 2014 May 27;82(21):1888-96. doi: 10.1212/WNL.0000000000000447. Epub 2014 Apr 30. PubMed PMID: 24789865; PubMed Central PMCID: PMC4105253.
  • Lee YS, Ashman T, Shang A, Suzuki W. Brief report: Effects of exercise and self-affirmation intervention after traumatic brain injury. NeuroRehabilitation. 2014 Jul 2. [Epub ahead of print] PubMed PMID: 24990010.
  • Suzuki WA, Naya Y. The perirhinal cortex. Annu Rev Neurosci. 2014 Jul 8;37:39-53. doi: 10.1146/annurev-neuro-071013-014207. PubMed PMID: 25032492.